Barinthus Bio is currently enrolling participants in the AVALON clinical trial, a Phase 1 study assessing the safety and tolerability of VTP-1000, an investigational immunotherapy for celiac disease. The trial aims to determine if VTP-1000 can help the immune system become more tolerant of gluten, potentially reducing symptoms caused by accidental gluten exposure in adults with celiac disease.
VTP-1000: A Targeted Immunotherapy
VTP-1000 is designed as a targeted immunotherapy to train the immune system to tolerate gluten while preserving its overall protective function. Celiac disease is a chronic autoimmune disorder where the ingestion of gluten leads to damage in the small intestine. Currently, the primary treatment is a strict gluten-free diet, which can be challenging to maintain and may not fully eliminate symptoms.
AVALON Trial Details
The AVALON trial is enrolling adults aged 18-65 years with celiac disease confirmed by biopsy within the past 10 years, who have been on a gluten-free diet for at least 12 months. The study is being conducted at multiple locations across the US, including Baltimore, MD, and Los Angeles, CA, with more locations planned. Participants may be eligible for compensation to help offset the costs of their time and travel.
Barinthus Bio's Focus
Barinthus Bio is a clinical-stage biopharmaceutical company focused on developing novel T cell immunotherapeutic candidates. Their aim is to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's guiding principle is to help people living with serious diseases and their families.
